TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00274937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Given subcutaneously
Study: NCT01211249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 (Part B)
Description: Capsule, dosage to be established based on results of Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part B)
Description: Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
Study: NCT00274937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiotherapy
Study: NCT02491346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional empirical glycemic control
Description: the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SGC directed glycemic control
Description: the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
Study: NCT00194753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 24 mg/m2 IV weekly x 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m2 PO daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
Study: NCT03328936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given personalized dose IV for predicted 3-day duration of severe neutropenia
Study: NCT00451503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Middle Ear Implant
Description: surgery
Study: NCT00381407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Description: Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal.
Study: NCT03328936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given personalized dose IV for predicted 5-day duration of severe neutropenia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01018784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
Study: NCT01929941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB047986
Description: INCB047986 tablets administered orally at the protocol specified dose and frequency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
Study: NCT03531632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD007 + MGA012
Description: MGD007 and MGA012 are administered by IV infusion.
Study: NCT00600119

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral, once daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-118
Description: 5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
Study: NCT03775707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks
Study: NCT02507804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient diary PROMs
Study: NCT03504046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas App
Description: The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
Study: NCT02490345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: gabapentin usage as adjunctive treatment for pain control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study: NCT03812237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (EWB) Early Weight Bearing (2 Weeks Post-op)
Description: Patient were permitted to progressively weightbear on their heel at 2 week post-op.
Study: NCT00206232

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spironolactone
Description: Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
Study: NCT01270802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Description: Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/emtricitabine/efavirenz
Description: Continued therapy with tenofovir/emtricitabine/efavirenz

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
Study: NCT04554056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW05
Description: Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MW05
Description: Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF
Description: PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
Study: NCT04244305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Endurance training in the form of treadmill/cycle-ergometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Endurance training in the form of treadmill/cycle-ergometry
Study: NCT02147119

Intervention type: PROCEDURE
Intervention: Coronary angiography
Study: NCT04062903

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Appointment
Description: The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed appointment
Description: After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
Study: NCT02130102

Intervention type: DEVICE
Intervention: The ModuLAAr Ambient Assisted Living System
Description: The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies
Study: NCT04493528

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meso-Jet, 2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meso-Jet, 2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meso-Jet, 2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Meso-Jet, 2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using needle-free liquid jet injection with different parameters (pressure, volume, injection technique). Anesthetic agent: 2% lidocaine with 1:100,000 epinephrine, dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Needle,2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Needle,2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Needle,2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Needle,2% lidocaine(xylocaine)
Description: Performing local dental anesthesia using syringe and needles, same as regular clinical practice. Anesthestic agent: 2% lidocaine with 1:100,000 epinephrine,dose: 0.3-2ml.
Study: NCT02507804

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Study: NCT01039857

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Neuro-Psychotherapy
Description: Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
Study: NCT02268929

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix Software
Description: Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek Smart Pix readout Device
Description: Smartpix device for data upload out from blood glucose meter devices
Study: NCT04377347

Intervention type: OTHER
Intervention: Time
Description: Exposure is the time from patients call the Emergency Medical Coordination Center to they are admitted to a neurosurgiocal department.
Study: NCT03666533

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial Direct Current Stimulation
Description: Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation
Description: Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
Study: NCT01762020

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M Cavilon No Sting Barrier Film
Description: Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Preparation
Description: standard creams
Study: NCT00644085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: oral administration of aspirin 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration of placebo
Study: NCT01550653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
Study: NCT02556567

Intervention type: OTHER
Group type: OTHER
Intervention: Fitbit® Charge Heart Rate (HR) wristband
Description: The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
Study: NCT01990157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB08
Description: Weekly intravenous administration in escalating doses.
Study: NCT03372239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod base formulation
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (salt) formulation
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (salt) formulation
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT01716481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
Study: NCT03360760

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: 60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: 100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: High dose of methotrexate (8-12g/m\^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: OTHER
Intervention: Ifosfamide
Description: 12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 12g/m\^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH

Intervention type: PROCEDURE
Group type: OTHER
Intervention: definitive surgery
Description: Including limb-sparing procedure and amputation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: definitive surgery
Description: Including limb-sparing procedure and amputation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre surgical chemotherapy
Description: chemotherapy that given before definitive surgery
Study: NCT04202640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Stimulation
Description: The technique of mechanical stimulation alternates between compression and decompression of the treated area. It aims to reestablish a good blood circulation and lymphatic drainage.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Massages
Description: Massages will be carried out according to a specific regime as specified in the study protocol. The massages will be done in 15 sessions of 30 minutes each, done twice a week and will consist of:~* One part muscle exercise~* One part skin work (drainage)
Study: NCT03239431

Intervention type: OTHER
Intervention: asthmatic exacerbation
Description: evaluate the risk factors, frequency and nature of asthma exacerbations
Study: NCT02913157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Orally administered Hydroxychloroquine
Study: NCT01067131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEV7C1
Description: capsule intravaginal application contains antigen coupled to virosomes

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PEV7C9
Description: capsule intravaginal application contains excipient only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEV7B2
Description: reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEV7B1
Description: reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
Study: NCT01633957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-based Warfarin Initiation model
Description: Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical factor-based warfarin initiation model
Description: Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
Study: NCT02473640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Study: NCT03369860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactivity of Experimental Condition
Description: The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
Study: NCT02745925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Study: NCT03205241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Description: n-3 PUFA capsules containing EPA and DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil capsules
Study: NCT01493752

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: beetroot juice
Description: 250mls daily beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beetroot juice
Description: 250mls daily beetroot juice
Study: NCT02175238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 691751 fasted
Description: single dose BI 691751 in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 691751 after high fat breakfast
Description: single dose BI 691751 after a standardised high fat breakfast
Study: NCT02535494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive training
Description: We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive training
Description: We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
Study: NCT03097783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane Lidocaine
Description: Intradermal injection
Study: NCT02293668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH 225IU and hMG 225IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSH 150IU and hMG 150IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 5mg and hMG 150IU
Study: NCT02700750

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT exam
Description: OCT exam
Study: NCT02742935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: A fully humanized anti-PD-1 monoclonal immunoglobulin (IgG4 subtype)